{"content":"<li class=\"n-box-item date-title\" data-end=\"1507003199\" data-start=\"1506916800\" data-txt=\"Monday, December 23, 2019\">Monday, October  2, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3298879\" data-ts=\"1506987473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298879-windstreamplus-2_3-seeks-injunction-against-default-claim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream +2.3% as it seeks injunction against default claim</a></h4><ul>   <li>Windstream (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) has asked a judge to rule that its 2015 asset transfer around the creation of Communications Sales &amp; Leasing (now Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>)) was legitimate, and doesn't constitute a <a href=\"https://seekingalpha.com/news/3297620-windstream-minus-5_6-percent-noteholder-claims-default-spin-deal\" target=\"_blank\">default as alleged</a> by bondholder Aurelius Capital.</li>    <li>Bonds had rallied on the news and shares followed suit today, <font color='green'>gaining 2.3%</font>. Windstream shares had <font color='red'>fallen 8.4%</font> last week after the default claim. <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='red'>fell 16%</font> in that time frame and <font color='red'>declined another 0.4%</font> today after JPMorgan <a href=\"https://seekingalpha.com/news/3298666-uniti-group-minus-1_8-percent-jpmorgan-throws-towel\" target=\"_blank\">downgraded to Neutral</a>.</li>    <li>Windstream's seeking an injunction barring the bond trustee from declaring a default, saying Aurelius made \"erroneous assertions\" to \"extort value through simultaneously purchasing credit default swaps to cash in on the very default it is manufacturing.\"</li>    <li>A CreditSights report says Windstream's likely to win its challenge with a \"simple and straightforward approach to counter default claims tied to what it sees as the clear and unambiguous language of the contract.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298879\" data-linked=\"Windstream +2.3% as it seeks injunction against default claim\" data-tweet=\"$WIN $WINMQ $UNIT - Windstream +2.3% as it seeks injunction against default claim https://seekingalpha.com/news/3298879-windstreamplus-2_3-seeks-injunction-against-default-claim?source=tweet\" data-url=\"https://seekingalpha.com/news/3298879-windstreamplus-2_3-seeks-injunction-against-default-claim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298874\" data-ts=\"1506983376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROX\" target=\"_blank\">TROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298874-tronoxminus-2_8-exxaro-launches-16m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronox -2.8% as Exxaro launches 16M-share secondary offering</a></h4><ul>     <li>Tronox (NYSE:<a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a>) <font color='red'>-2.8%</font> after-hours as it confirms that Exxaro Resources (<a href='https://seekingalpha.com/symbol/EXXAY' title='Exxaro Resources Ltd. ADR'>OTCPK:EXXAY</a>) plans a <a href=\"https://seekingalpha.com/pr/16957166-tronox-limited-announces-secondary-public-offering-exxaro-resources-limited\" target=\"_blank\">secondary offering</a> of 16M common shares, with an underwriters option to purchase up to 2.4M additional shares.</li>     <li>The selling shareholder will receive all net proceeds from the offering.</li>     <li>If the offering is completed, Exxaro's ownership in TROX would be reduced to 29.4%, assuming no exercise of the underwriters option, and its right to nominate directors to TROX's board would drop to two members from three members currently.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298874\" data-linked=\"Tronox -2.8% as Exxaro launches 16M-share secondary offering\" data-tweet=\"$TROX $TROX $EXXAY - Tronox -2.8% as Exxaro launches 16M-share secondary offering https://seekingalpha.com/news/3298874-tronoxminus-2_8-exxaro-launches-16m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3298874-tronoxminus-2_8-exxaro-launches-16m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298868\" data-ts=\"1506981341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298868-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+17.1%</font>. <a href='https://seekingalpha.com/symbol/COHR' title='Coherent, Inc.'>COHR</a> <font color='green'>+15.1%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+2.1%</font>.</li>     <li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='red'>-20.0%</font>. <a href='https://seekingalpha.com/symbol/MPLX' title='MPLX LP'>MPLX</a> <font color='red'>-4.0%</font>. <a href='https://seekingalpha.com/symbol/OZM' title='Och-Ziff Capital Management Group LLC'>OZM</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='red'>-2.8%</font>. <a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Co.'>CPE</a> <font color='red'>-2.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298868\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ECYT $COHR $ACRX - After Hours Gainers / Losers https://seekingalpha.com/news/3298868-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298868-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298864\" data-ts=\"1506978711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZG\" target=\"_blank\">PZG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298864-paramount-gold-to-launch-public-offering-private-placement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paramount Gold to launch public offering, private placement</a></h4><ul>     <li>Paramount Gold Nevada (NYSEMKT:<a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a>) <font color='red'>-8.9%</font> after-hours as it announces a <a href=\"https://seekingalpha.com/pr/16957059-paramount-gold-nevada-announces-public-offering-common-stock\" target=\"_blank\">public stock offering</a> and a private placement of as many as 1.8M common shares at the same price as in the public offering.</li>     <li>PZG says it plans to use the proceeds to complete the pre-feasibility study on the Grassy Mountain Project and towards permitting.</li>     <li>The closings of the public offering and private placement are expected to occur on or about Oct. 12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298864\" data-linked=\"Paramount Gold to launch public offering, private placement\" data-tweet=\"$PZG - Paramount Gold to launch public offering, private placement https://seekingalpha.com/news/3298864-paramount-gold-to-launch-public-offering-private-placement?source=tweet\" data-url=\"https://seekingalpha.com/news/3298864-paramount-gold-to-launch-public-offering-private-placement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298863\" data-ts=\"1506978382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298863-centurylink-federal-antitrust-ok-to-buy-level-3-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink has federal antitrust OK to buy Level 3 (updated)</a></h4><ul>   <li>CenturyLink (<a href=\"http://seekingalpha.com/symbol/CTL\" target=\"_blank\">CTL</a> <font color='green'>+2.2%</font>) has gotten federal antitrust approval for its $34B buyout of Level 3 Communications (<a href=\"http://seekingalpha.com/symbol/LVLT\" target=\"_blank\">LVLT</a> <font color='green'>+1.2%</font>)</li>    <li>It's also received the OK from 24 states and districts, with a final regional hurdle set to clear with California reportedly set to give conditional approval to the deal.</li>    <li>A California administrative law judge proposed approving a settlement approving the deal if the combined company spends at least $232M in the state over three years. That needs final approval with an earliest hearing set for Oct. 12.</li><li><strong>Updated:</strong> The <a href=\"https://seekingalpha.com/pr/16957179-u-s-department-justice-clears-centurylinks-acquisition-level-3\" target=\"_blank\">approval by DOJ is conditional</a>, requiring the combined company to divest Level 3 metro network assets in three metros (Albuquerque, N.M.; Boise, Idaho; and Tucson, Ariz.) and let go of 24 strands of dark fiber connecting 30 specified city-pairs countrywide.</li><li><strong>What's next:</strong> awaiting approval from the FCC and the California PUC.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294853-centurylink-updates-level-3-closing-time-frame\" target=\"_blank\">CenturyLink updates Level 3 closing time frame</a> (Sep. 12 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294473-california-puc-proposes-approved-settlement-ctl-lvlt-deal\" target=\"_blank\">California PUC proposes approved settlement for CTL/LVLT deal</a> (Sep. 08 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291382-new-jersey-oks-centurylinks-level-3-buyout-california-last\" target=\"_blank\">New Jersey OKs CenturyLink's Level 3 buyout; California is last</a> (Aug. 23 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298863\" data-linked=\"CenturyLink has federal antitrust OK to buy Level 3 (updated)\" data-tweet=\"$CTL $CTL $LVLT - CenturyLink has federal antitrust OK to buy Level 3 (updated) https://seekingalpha.com/news/3298863-centurylink-federal-antitrust-ok-to-buy-level-3-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3298863-centurylink-federal-antitrust-ok-to-buy-level-3-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298856\" data-ts=\"1506977268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VICL\" target=\"_blank\">VICL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298856-mid-stage-study-may-suffice-under-lui-for-vicals-antifungal-vlminus-2397-shares-ahead-37\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-stage study may suffice under LUI for Vical&#39;s antifungal VL-2397; shares ahead 37% after hours</a></h4><ul><li>Thinly traded nano cap Vical (NASDAQ:<a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a>) is up&nbsp;<font color='green'>37%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16957058-vical-announces-antifungal-vlminus-2397-eligible-limited-use-indication-approval-fda-based\" target=\"_blank\">announcement </a>that the FDA has advised it that a single successful Phase 2 clinical trial may be sufficient to support approval of antifungal VL-2397 under Limited Use Indication &#40;LUI&#41;&nbsp;status.</li><li>The company intends to launch the mid-stage study this quarter in acute leukemia and allogeneic hematopoietic cell transplant patients who have invasive aspergillosis.</li><li>LUI is a provision under the <a href=\"http://www.cidrap.umn.edu/news-perspective/2016/12/how-21st-century-cures-act-could-boost-new-antibiotics\" target=\"_blank\">21st Century Cures Act of 201</a>6 that allows drug makers to provide certain newly approved antibiotics to a limited population of patients. Approvals may be based on smaller datasets in order to make them available to patients in need.</li><li>VL-2397, licensed from Astellas Pharma in 2015, is an isolate of a leaf litter fungus collected in Malaysia.</li><li>Management will host a conference call tomorrow at 12 noon ET to discuss the Phase 2 trial design.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298856\" data-linked=\"Mid-stage study may suffice under LUI for Vical&#39;s antifungal VL-2397; shares ahead 37% after hours\" data-tweet=\"$VICL $BBI - Mid-stage study may suffice under LUI for Vical&#39;s antifungal VL-2397; shares ahead 37% after hours https://seekingalpha.com/news/3298856-mid-stage-study-may-suffice-under-lui-for-vicals-antifungal-vlminus-2397-shares-ahead-37?source=tweet\" data-url=\"https://seekingalpha.com/news/3298856-mid-stage-study-may-suffice-under-lui-for-vicals-antifungal-vlminus-2397-shares-ahead-37\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298850\" data-ts=\"1506977031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298850-reuters-blackberry-patent-monetization-chief-left-for-health-tech-firm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: BlackBerry patent-monetization chief left for health tech firm</a></h4><ul>   <li>The head of the patent portfolio for BlackBerry (<a href=\"http://seekingalpha.com/symbol/BBRY\" target=\"_blank\">BBRY</a> <font color='green'>+1.4%</font>) has <a href=\"https://www.reuters.com/article/us-blackberry-patents/blackberrys-patent-strategy-head-exits-joins-health-tech-firm-sources-idUSKCN1C72NS\" target=\"_blank\">exited to join a health technology company</a>, Reuters reports.</li>    <li>Mark Kokes joined NantWorks (an incubator of sorts founded by billionaire Patrick Soon-Shiong) last month, the news service says.</li><li>He's apparently following in the footsteps of Ron Louks (BlackBerry's president for devices and emerging solutions), who joined publicly traded NantWorks unit NantHealth (<a href=\"http://seekingalpha.com/symbol/NH\" target=\"_blank\">NH</a> <font color='green'>+14.3%</font>) as its chief operating officer in May.</li>    <li>Kokes' role from mid-2014 was to help BlackBerry make money from its patent portfolio. He's still listed in that capacity on LinkedIn.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298850\" data-linked=\"Reuters: BlackBerry patent-monetization chief left for health tech firm\" data-tweet=\"$BB $BB $NH - Reuters: BlackBerry patent-monetization chief left for health tech firm https://seekingalpha.com/news/3298850-reuters-blackberry-patent-monetization-chief-left-for-health-tech-firm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298850-reuters-blackberry-patent-monetization-chief-left-for-health-tech-firm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298842\" data-ts=\"1506976465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPE\" target=\"_blank\">CPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298842-callon-petroleumminus-4-after-cutting-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Callon Petroleum -4% after cutting production guidance</a></h4><ul>     <li>Callon Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Co.'>CPE</a>) <font color='red'>-4%</font> after-hours as it <a href=\"https://seekingalpha.com/pr/16957055-callon-petroleum-company-provides-updated-production-guidance\" target=\"_blank\">lowers its Q3 production guidance</a> range to 22.4K-22.6K boe/day from its earlier outlook for 23K-25K boe/day.</li>     <li>CPE also revised its full-year 2017 production guidance to 22K-23K boe/day (78% oil), reflect the revised Q3 guidance.</li>     <li>CPE cites more non-productive time  during the completion of wells in Q3 caused by a ~20% reduction in average efficiency across all  vendors involved with completion operations vs. Q2, resulting in extended cycle times for wells and delays in associated production contributions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298842\" data-linked=\"Callon Petroleum -4% after cutting production guidance\" data-tweet=\"$CPE - Callon Petroleum -4% after cutting production guidance https://seekingalpha.com/news/3298842-callon-petroleumminus-4-after-cutting-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3298842-callon-petroleumminus-4-after-cutting-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298833\" data-ts=\"1506976209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBB\" target=\"_blank\">CBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298833-cincinnati-bell-closes-201m-purchase-of-onx\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell closes $201M purchase of OnX</a></h4><ul>   <li>Cincinnati Bell (<a href=\"http://seekingalpha.com/symbol/CBB\" target=\"_blank\">CBB</a> <font color='green'>+2%</font>) has <a href=\"https://seekingalpha.com/pr/16957024-cincinnati-bell-inc-completes-acquisition-onx-enterprise-solutions-creates-hybrid-solutions\" target=\"_blank\">wrapped its $201M acquisition</a> of service provider OnX Enterprise Solutions.</li>    <li>Combining OnX and CBTS, Cincinnati Bell's enterprise IT services business, gives the company a stronger platform in the U.S. and Canada to pursue an expected $250B global spending on cloud services, it says.</li>    <li>As a unit, the combination will offer managed cloud computing and data center services, and end-to-end communications services with subject matter expertise in support of sales, installation, operation, and maintenance, according to Cincinnati Bell.</li>    <li>The closing of the deal means new debt for Cincinnati Bell: a five-year $200M senior secured revolving credit facility and a seven-year $600M senior secured term loan facility.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277654-cincinnati-bell-buys-hawaiian-telecom-30_75-share\" target=\"_blank\">Cincinnati Bell buys Hawaiian Telecom for $30.75/share</a> (Jul. 10 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298833\" data-linked=\"Cincinnati Bell closes $201M purchase of OnX\" data-tweet=\"$CBB - Cincinnati Bell closes $201M purchase of OnX https://seekingalpha.com/news/3298833-cincinnati-bell-closes-201m-purchase-of-onx?source=tweet\" data-url=\"https://seekingalpha.com/news/3298833-cincinnati-bell-closes-201m-purchase-of-onx\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298815\" data-ts=\"1506974112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PICO\" target=\"_blank\">PICO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298815-pico-holdings-to-explore-strategic-alternatives-including-potential-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PICO Holdings  to explore strategic alternatives, including potential sale</a></h4><ul>     <li>PICO Holdings (<a href='https://seekingalpha.com/symbol/PICO' title='PICO Holdings Inc.'>PICO</a> <font color='green'>+6.9%</font>) is higher after saying this morning that it hired JMP Securities to help it <a href=\"https://seekingalpha.com/pr/16955840-pico-holdings-inc-announces-exploration-strategic-alternatives-including-possible-sale\" target=\"_blank\">explore strategic alternatives</a> including a merger or sale of the company.</li>     <li>PICO says it has \"made significant progress streamlining its focus of operations and  cost structure by reducing overhead, and selling its agribusiness, real  estate, and oil and gas operations.\"</li>     <li>PICO&rsquo;s primary remaining asset and operation is Vidler Water Co., which owns ~8K acre-feet of permitted water credits  that are available to provide a sustainable water supply in the Reno, Nev., area.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298815\" data-linked=\"PICO Holdings  to explore strategic alternatives, including potential sale\" data-tweet=\"$PICO - PICO Holdings to explore strategic alternatives, including potential sale https://seekingalpha.com/news/3298815-pico-holdings-to-explore-strategic-alternatives-including-potential-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3298815-pico-holdings-to-explore-strategic-alternatives-including-potential-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298814\" data-ts=\"1506973777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298814-hertz-and-avis-budget-spike-in-late-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hertz and Avis Budget spike in late trading</a></h4><ul> <li>Hertz Global (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='green'>+5.2%</font>) and Avis Budget (<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='green'>+2.9%</font>) have spiked higher in late trading.</li> <li>While there doesn't appear to be any specific news out on the car rental companies, an elevated level of options activity on the two stocks has added to share price volatility.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298814\" data-linked=\"Hertz and Avis Budget spike in late trading\" data-tweet=\"$HTZ $HTZ $CAR - Hertz and Avis Budget spike in late trading https://seekingalpha.com/news/3298814-hertz-and-avis-budget-spike-in-late-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3298814-hertz-and-avis-budget-spike-in-late-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298813\" data-ts=\"1506973719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298813-sellas-life-sciences-to-collaborate-merck-on-clinical-trial-assessing-combo-treatment-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SELLAS Life Sciences to collaborate with Merck on clinical trial assessing combo treatment for range of cancers; merger partner Galena up 6%</a></h4><ul><li>Privately held SELLAS Life Sciences Group inks a clinical trial collaboration <a href=\"https://seekingalpha.com/pr/16956008-sellas-enters-clinical-trial-collaboration-supply-agreement-merck-and-co-inc-kenilworth-n-j\" target=\"_blank\">agreement </a>with Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+0.8%</font>)&nbsp;evaluating the combination of galinpepimut-S and Keytruda (pembrolizumab) in a range of cancers, including both blood cancers and solid tumors in a Phase 1/2 study.</li><li>The trial will enroll patients with Wilms tumor-1 (WT1)-positive relapsed/refractory tumors. Targeted cancers will be: colorectal, ovarian, small cell lung, triple-negative breast and AML.</li><li>SELLAS merger partner Galena Biopharma (GALE <font color='green'>+6.4%</font>) is up on more than triple normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298813\" data-linked=\"SELLAS Life Sciences to collaborate with Merck on clinical trial assessing combo treatment for range of cancers; merger partner Galena up 6%\" data-tweet=\"$MRK $MRK $SLS - SELLAS Life Sciences to collaborate with Merck on clinical trial assessing combo treatment for range of cancers; merger partner Galena up 6% https://seekingalpha.com/news/3298813-sellas-life-sciences-to-collaborate-merck-on-clinical-trial-assessing-combo-treatment-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3298813-sellas-life-sciences-to-collaborate-merck-on-clinical-trial-assessing-combo-treatment-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298810\" data-ts=\"1506973292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMP\" target=\"_blank\">CMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298810-compass-minerals-upgraded-to-buy-monness-crespi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Compass Minerals upgraded to Buy at Monness Crespi</a></h4><ul>     <li>Compass Minerals (<a href='https://seekingalpha.com/symbol/CMP' title='Compass Minerals International, Inc.'>CMP</a> <font color='green'>+1.6%</font>) is upgraded to Buy from Neutral with a $76 price target at Monness Crespi following the stock's recent slide and <a href=\"https://seekingalpha.com/news/3297085\" target=\"_blank\">last week</a>'s investor event which made clear the potential free cash flow growth during the next few years.</li><li>Monness says its Buy  rating is based on a return to more normal winter weather - and La Ni&ntilde;a offers some confidence of that outcome - but even without a snowy winter, the firm expects improved earnings with limited downside to share price given  current levels.</li><li>With the end of a capital investment program, Monness says free cash flow will increase substantially during the next few years, accelerating EPS growth through paying down debt and higher dividends, on top of a nearly 5% yield; as such, it sees little downside risk but significant opportunity for meaningful earnings growth during the next two years.</li>          <li>Source:&nbsp;Briefing.com</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298810\" data-linked=\"Compass Minerals upgraded to Buy at Monness Crespi\" data-tweet=\"$CMP - Compass Minerals upgraded to Buy at Monness Crespi https://seekingalpha.com/news/3298810-compass-minerals-upgraded-to-buy-monness-crespi?source=tweet\" data-url=\"https://seekingalpha.com/news/3298810-compass-minerals-upgraded-to-buy-monness-crespi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298808\" data-ts=\"1506973076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRSP\" target=\"_blank\">CRSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298808-new-chief-crispr-therapeutics-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at CRISPR Therapeutics; shares up 3%</a></h4><ul><li>CRISPR Therapeutics (<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='green'>+3.4%</font>) <a href=\"https://seekingalpha.com/pr/16955996-crispr-therapeutics-announces-promotion-samarth-kulkarni-ph-d-chief-executive-officer\" target=\"_blank\">promotes </a>President Samarth Kulkarni, Ph.D., to CEO effective December 1 succeeding co-founder Rodger Novak, M.D., who will step down due to personal reasons.</li><li>Dr. Kulkarni, previously with consulting firm McKinsey, joined the firm as Chief Business Officer in August 2015.</li><li>Dr. Novak will continue to serve on the board.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298808\" data-linked=\"New chief at CRISPR Therapeutics; shares up 3%\" data-tweet=\"$CRSP - New chief at CRISPR Therapeutics; shares up 3% https://seekingalpha.com/news/3298808-new-chief-crispr-therapeutics-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3298808-new-chief-crispr-therapeutics-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298805\" data-ts=\"1506972054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298805-snapchat-ad-growth-to-be-slower-expected-emarketer-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snapchat ad growth to be slower than expected, eMarketer says</a></h4><ul>   <li>Snapchat (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='green'>+2.4%</font>) ad revenue should hit just over $774M this year, eMarketer says -- <a href=\"https://www.emarketer.com/Article/eMarketer-Lowers-Snapchats-Ad-Revenue-Forecast-2017/1016554\" target=\"_blank\">slower than the prediction</a> the research firm made in the spring.</li>    <li>In March, eMarketer saw $900M in worldwide ad revenues for Snapchat, but user growth has been slower than expected.</li>    <li>U.S. ad revenues are expected to come in at $642.5M, down from March's $770M prediction.</li>    <li>But it still expects strong growth in the coming two years, with U.S. ad revenues topping $2B by 2019 (and passing Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+1.4%</font>) in that measure next year, $1.18B to $1.16B).</li>    <li>Instagram (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='red'>-0.7%</font>) is going to widen its U.S. lead over Snapchat in the next few years, eMarketer says, bringing in $3B this year and rising to $6.84B in 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298805\" data-linked=\"Snapchat ad growth to be slower than expected, eMarketer says\" data-tweet=\"$SNAP $SNAP $TWTR - Snapchat ad growth to be slower than expected, eMarketer says https://seekingalpha.com/news/3298805-snapchat-ad-growth-to-be-slower-expected-emarketer-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3298805-snapchat-ad-growth-to-be-slower-expected-emarketer-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298803\" data-ts=\"1506971752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWP\" target=\"_blank\">BWP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298803-boardwalk-southwestern-restructure-firm-transportation-service-agreements\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boardwalk, Southwestern restructure firm transportation service agreements</a></h4><ul>     <li>Boardwalk Pipeline (<a href='https://seekingalpha.com/symbol/BWP' title='Boardwalk Pipeline Partners, LP'>BWP</a> <font color='green'>+1.2%</font>) files with the FERC seeking approval to <a href=\"https://seekingalpha.com/pr/16956121-boardwalk-restructures-extends-firm-transportation-service-agreements-southwestern-energy\" target=\"_blank\">restructure some of its existing firm transportation agreements</a> and enter into new firm transportation agreements with Sourthwestern Energy (<a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Co.'>SWN</a> <font color='green'>+1.8%</font>).</li>     <li>BWP says the agreement lowers the contract quantities for SWN's existing firm transportation  contracts on the Fayetteville Lateral through 2020 and adds new long-term firm transportation agreements on the Fayetteville and Greenville Laterals through 2030.</li>     <li>BWP says the restructuring of the transportation  agreements will help Texas Gas achieve greater long-term revenue generation and provides future revenue upside through SWN's volume commitment of flowing gas from the Fayetteville and Moorefield plays.</li>     <li>SWN expects the new agreement, effective Nov. 1, will <a href=\"https://seekingalpha.com/pr/16956148-southwestern-energy-successfully-renegotiates-fayetteville-firm-transportation-agreement\" target=\"_blank\">provide ~$70M in savings</a> during 2017-20 through the reduction of current excess capacity while guaranteeing future flexible takeaway capacity through 2030 at competitive rates.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298803\" data-linked=\"Boardwalk, Southwestern restructure firm transportation service agreements\" data-tweet=\"$BWP $BWP $SWN - Boardwalk, Southwestern restructure firm transportation service agreements https://seekingalpha.com/news/3298803-boardwalk-southwestern-restructure-firm-transportation-service-agreements?source=tweet\" data-url=\"https://seekingalpha.com/news/3298803-boardwalk-southwestern-restructure-firm-transportation-service-agreements\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298802\" data-ts=\"1506971530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298802-sinclairminus-4_1-on-report-fox-sees-sweeter-affiliate-deal-from-ion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinclair -4.1% on report Fox sees sweeter affiliate deal from Ion</a></h4><ul>   <li>Sinclair Broadcast Group (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color='red'>-4.1%</font>) is sinking again on a new sign that Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+0.9%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+1.1%</font>) might drop it as an affiliate partner, with word that Fox is getting a sweeter affiliate offer from Ion Media Networks.</li>    <li>A better offer from Ion would <a href=\"https://www.thestreet.com/story/14325671/1/ion-media-sweetens-fox-offer.html\" target=\"_blank\">combine its local broadcast stations</a> with Fox's, TheStreet says, in a deal that could get Fox as much of 90% of the venture's retransmission fees.</li>    <li>A successful deal would mean Fox transferring ownership of 28 mainly metro TV stations to the JV, joining 60 stations owned by Ion.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285441-sinclair-broadcast-minus-7_6-percent-amid-reports-fox-dump-affiliation\" target=\"_blank\">Sinclair Broadcast -7.6% amid reports Fox could dump affiliation</a> (Aug. 03 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298802\" data-linked=\"Sinclair -4.1% on report Fox sees sweeter affiliate deal from Ion\" data-tweet=\"$FOX $FOX $FOXA - Sinclair -4.1% on report Fox sees sweeter affiliate deal from Ion https://seekingalpha.com/news/3298802-sinclairminus-4_1-on-report-fox-sees-sweeter-affiliate-deal-from-ion?source=tweet\" data-url=\"https://seekingalpha.com/news/3298802-sinclairminus-4_1-on-report-fox-sees-sweeter-affiliate-deal-from-ion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298800\" data-ts=\"1506970532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298800-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/QTRH' title='Quarterhill Inc.'>QTRH</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298800\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$VHC $QTRH $SNCR - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3298800-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298800-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298797\" data-ts=\"1506970301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATEC\" target=\"_blank\">ATEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298797-alphatec-up-40-after-adding-former-nuvasive-execs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alphatec up 40% after adding former NuVasive execs</a></h4><ul><li>Patrick Miles has been appointed to the executive chairman role. Current CEO Terry Rich will report to Miles. Quentin Blackford has been added to the board. The two are also buying more than $3.5M of Alphatec (<a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a> <font color='green'>+38.5%</font>) stock.</li><li>Both previously held key roles at NuVasive (<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a> <font color='red'>-1.2%</font>).</li><li>Source: <a href=\"https://seekingalpha.com/pr/16956420-alphatec-accelerates-business-transformation-additional-spine-experienced-leadership\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3298797\" data-linked=\"Alphatec up 40% after adding former NuVasive execs\" data-tweet=\"$ATEC $ATEC $NUVA - Alphatec up 40% after adding former NuVasive execs https://seekingalpha.com/news/3298797-alphatec-up-40-after-adding-former-nuvasive-execs?source=tweet\" data-url=\"https://seekingalpha.com/news/3298797-alphatec-up-40-after-adding-former-nuvasive-execs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298796\" data-ts=\"1506969955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298796-morgan-stanley-weighs-in-on-railroads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley weighs in on railroads</a></h4><ul> <li>Morgan Stanley check in on the railroad sector, citing some broad concerns on pricing and the risk to earnings growth.</li> <li>The firm sees CSX (<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='red'>-2.8%</font>) as the weakest of the bunch, downgrading shares to Underweight from Equal-weight.</li> <li>Union Pacific (<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color='red'>-0.8%</font>)&nbsp;is lowered to Equal-weight from Overweight due to its exposure to coal and auto.</li> <li>MS is more optimistic on Canadian National (<a href='https://seekingalpha.com/symbol/CNI' title='Canadian National Railway Company'>CNI</a> <font color='red'>-0.6%</font>) and Canadian Pacific (<a href='https://seekingalpha.com/symbol/CP' title='Canadian Pacific Railway Limited'>CP</a> <font color='red'>-0.6%</font>)&nbsp;due to the expectation for higher volume of Canadian crude oil transport.</li> <li>Sources: CNBC and Bloomberg</li> <li>Railroad stock YTD scorecard: CSX +46%, CNI +22%, CP +12%, UNP +10%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298796\" data-linked=\"Morgan Stanley weighs in on railroads\" data-tweet=\"$CSX $CSX $UNP - Morgan Stanley weighs in on railroads https://seekingalpha.com/news/3298796-morgan-stanley-weighs-in-on-railroads?source=tweet\" data-url=\"https://seekingalpha.com/news/3298796-morgan-stanley-weighs-in-on-railroads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298792\" data-ts=\"1506969061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298792-department-store-sector-reeling-on-nordstrom-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Department store sector reeling on Nordstrom news</a></h4><ul> <li>Department store stocks are lower after the Nordstrom family is reported to have hit some roadblocks in its effort to take the department store chain private.</li> <li>J.C Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-6.7%</font>), Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-5.2%</font>), Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='red'>-4.6%</font>), Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-2.7%</font>) and Sears Holdings (SHLD <font color='red'>-3%</font>) have all shed some of their gains fueled recently by M&amp;A speculation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298687-nordstrom-slides-report-go-private-obstacles\" target=\"_blank\">Nordstrom slides on report of go-private obstacles</a> (Oct. 2)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298792\" data-linked=\"Department store sector reeling on Nordstrom news\" data-tweet=\"$JCP $JCP $M - Department store sector reeling on Nordstrom news https://seekingalpha.com/news/3298792-department-store-sector-reeling-on-nordstrom-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3298792-department-store-sector-reeling-on-nordstrom-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298783\" data-ts=\"1506967997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGM\" target=\"_blank\">MGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298783-analysts-update-on-mgm-resorts-after-las-vegas-tragedy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts update on MGM Resorts after Las Vegas tragedy</a></h4><ul> <li>Nomura thinks MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) will see an elevated level of cancellations in Q4 due to the mass shooting near the Mandalay Bay hotel resort, but that the financial impact will be recorded as an one-time quarterly charge and be limited over the long term.</li> <li>MGM is still one of the favorite stocks of Nomura casino sector analyst Harry Curtis.</li> <li>The note from Curtis advises investors that all the positive aspects of the MGM growth story are still in play.</li> <li>Morningstar analyst Dan Wasiolek is also <a href=\"https://www.cnbc.com/2017/10/02/casino-stocks-fall-led-by-mandalay-bay-owner-mgm-after-las-vegas-shooting.html\" target=\"_blank\">weighing in</a> on MGM. \"Barring another tragic event in the gaming region the impact to travel and operators in the region could likely prove short-lived and pullbacks like these can be long-term add opportunities,\" says Wasiole.</li> <li>Shares of MGM are&nbsp;<font color='red'>down 4.79%</font>&nbsp;on the day on volume almost 4X normal activity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298598-mgm-resorts-mass-shooting-las-vegas\" target=\"_blank\">MGM Resorts down after mass shooting in Las Vegas</a> (Oct. 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298659-mgm-resorts-responds-las-vegas-mass-shooting-tragedy\" target=\"_blank\">MGM Resorts responds to Las Vegas mass shooting tragedy</a> (Oct. 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298783\" data-linked=\"Analysts update on MGM Resorts after Las Vegas tragedy\" data-tweet=\"$MGM - Analysts update on MGM Resorts after Las Vegas tragedy https://seekingalpha.com/news/3298783-analysts-update-on-mgm-resorts-after-las-vegas-tragedy?source=tweet\" data-url=\"https://seekingalpha.com/news/3298783-analysts-update-on-mgm-resorts-after-las-vegas-tragedy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298778\" data-ts=\"1506967259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298778-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/OLN' title='Olin Corporation'>OLN</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> PGH <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/PDS' title='Precision Drilling Corporation'>PDS</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298778\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$WLB $ROSE $VHI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3298778-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298778-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298775\" data-ts=\"1506966361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298775-mallinckrodt-in-licenses-inhalable-xenon-gas-for-up-to-35m-trims-h2-2017-non-gaap-eps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt in-licenses inhalable xenon gas for up to $35M; trims H2 2017 non-GAAP EPS guidance $0.10 - 0.15; shares up 3%</a></h4><ul><li>Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='green'>+3.2%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16955874-mallinckrodt-licenses-inhaled-xenon-gas-therapy-development-product\" target=\"_blank\">announcement </a>of a licensing deal with NeuroproteXeon for its investigational pharmaceutical-grade xenon gas for inhalation for the potential resuscitation of patients who have experienced cardiac arrest.</li><li>Under the terms of the agreement, MNK will pay $10 up front, up to $25M in milestones and tiered royalties on net sales. NeuroproteXeon will continue to be responsible for development costs and will manage such activities in collaboration with MNK.</li><li>MNK says it expects dilution of $0.10 - 0.15 to non-GAAP EPS for the rest of the year and modest dilution in 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298775\" data-linked=\"Mallinckrodt in-licenses inhalable xenon gas for up to $35M; trims H2 2017 non-GAAP EPS guidance $0.10 - 0.15; shares up 3%\" data-tweet=\"$MNK - Mallinckrodt in-licenses inhalable xenon gas for up to $35M; trims H2 2017 non-GAAP EPS guidance $0.10 - 0.15; shares up 3% https://seekingalpha.com/news/3298775-mallinckrodt-in-licenses-inhalable-xenon-gas-for-up-to-35m-trims-h2-2017-non-gaap-eps?source=tweet\" data-url=\"https://seekingalpha.com/news/3298775-mallinckrodt-in-licenses-inhalable-xenon-gas-for-up-to-35m-trims-h2-2017-non-gaap-eps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298776\" data-ts=\"1506965792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATUS\" target=\"_blank\">ATUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298776-disneyplus-1_5-altice-usaplus-1_1-after-deal-averts-channel-blackout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney +1.5%, Altice USA +1.1% after deal averts channel blackout</a></h4><ul>   <li>Walt Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='green'>+1.5%</font>) is the Dow's top gainer today, and Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) is outstripping the broader market as well, <font color='green'>up 1.1%</font>, after word that the two <a href=\"https://seekingalpha.com/news/3298573-altice-usa-disney-reach-deal-program-interruption\" target=\"_blank\">averted a blackout on Altice's Optimum systems</a> with an agreement in principle on a carriage deal.</li>    <li>Optimum has 3.1M subscribers in New York, New Jersey, Pennsylvania and Connecticut.</li>    <li>The fact that the deal happened at all, likely with higher fees charged to carry ESPN, is a \"very bullish sign for Disney,\" writes analyst Michael Nathanson. \"The Altice renewal is the first deal in the next cycle of ABC/ESPN affiliate agreements and should serve as a template for the next wave of deals.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298776\" data-linked=\"Disney +1.5%, Altice USA +1.1% after deal averts channel blackout\" data-tweet=\"$ATUS $ATUS $DIS - Disney +1.5%, Altice USA +1.1% after deal averts channel blackout https://seekingalpha.com/news/3298776-disneyplus-1_5-altice-usaplus-1_1-after-deal-averts-channel-blackout?source=tweet\" data-url=\"https://seekingalpha.com/news/3298776-disneyplus-1_5-altice-usaplus-1_1-after-deal-averts-channel-blackout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298773\" data-ts=\"1506965241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LENS\" target=\"_blank\">LENS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298773-presbia-continues-rally-up-18-ahead-of-european-medical-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Presbia continues rally, up 18% ahead of European medical conference</a></h4><ul><li>Thinly traded nano cap Presbia PLC (<a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='green'>+18.1%</font>) continues northward on triple normal volume, albeit on turnover of only 40K shares. The stock has almost doubled in a month.</li><li>Next week, the company will <a href=\"https://seekingalpha.com/pr/16956063-presbia-participate-xxxv-congress-european-society-cataract-and-refractive-surgeons\" target=\"_blank\">participate </a>in the European Society of Cataract and Refractive Surgeons Congress in Lisbon, October 7 - 11. Several surgeons who have implanted the Flexivue Microlens under the FDA study will be sharing their experiences.</li><li>Its U.S. marketing application for Flexivue is on tap this quarter with approval expected next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298773\" data-linked=\"Presbia continues rally, up 18% ahead of European medical conference\" data-tweet=\"$LENS - Presbia continues rally, up 18% ahead of European medical conference https://seekingalpha.com/news/3298773-presbia-continues-rally-up-18-ahead-of-european-medical-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3298773-presbia-continues-rally-up-18-ahead-of-european-medical-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298771\" data-ts=\"1506964271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298771-roku-retrenches-from-huge-ipo-surgeminus-10_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku retrenches from huge IPO surge, -10.8%</a></h4><ul>   <li>After <font color='green'>surging 64%</font> in its IPO debut Thursday and building with double-digit gains again Friday, Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is giving back some gains today, <font color='red'>down 10.8%</font>.</li>    <li>Shares are still about 70% above its IPO price of $14.</li>    <li>After Friday's higher close, Tae Kim on CNBC <a href=\"https://www.cnbc.com/2017/09/29/wall-street-industry-experts-are-skeptical-over-rokus-soaring-ipo.html\" target=\"_blank\">noted some skepticism among observers</a> who note that the company's offerings could be rapidly commoditized.</li>    <li>\"Roku had first mover advantage, the channels like them and they are a very lean company, all positive,\" Moor Insights &amp; Strategy's Patrick Moorhead says. \"What concerns me is that the company becomes commoditized as they're really not bringing anything unique to the table anymore in a rapidly growing market.</li>    <li>\"Roku seems to be making it work in its transition away from player sales and towards monetizing its audience, Jackdaw Research's Jan Dawson tells Kim, \"but it continues to go up against three of the biggest companies in the consumer technology industry, all of which are increasingly building voice controls and other advanced features into their TV boxes and platforms in a way that may be tough for Roku to counter.\"</li>    <li>Roku today rolled out a <a href=\"https://seekingalpha.com/pr/16956371-roku-announces-new-streaming-player-line-higher-performance-convenience-greater-value\" target=\"_blank\">new line of streaming devices</a> along with the <a href=\"https://seekingalpha.com/pr/16956338-new-roku-os-8-delivers-enhanced-entertainment-features\" target=\"_blank\">latest iteration of its operating system</a>, Roku OS 8. Five new devices ranging in suggested retail price from a basic $29.99 to the Roku Ultra's $99.99 offer a range of streaming TV options, and the new OS unveils a Smart Guide that blends over-the-air broadcast options and streaming selections.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298771\" data-linked=\"Roku retrenches from huge IPO surge, -10.8%\" data-tweet=\"$ROKU - Roku retrenches from huge IPO surge, -10.8% https://seekingalpha.com/news/3298771-roku-retrenches-from-huge-ipo-surgeminus-10_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3298771-roku-retrenches-from-huge-ipo-surgeminus-10_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298769\" data-ts=\"1506964178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298769-mylan-launches-generic-version-of-mercks-cancidas-antifungal-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan launches generic version of Merck&#39;s Cancidas antifungal; shares ahead 2%</a></h4><ul><li>Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+1.6%</font>) <a href=\"https://seekingalpha.com/pr/16956816-mylan-launches-generic-cancidas-injection\" target=\"_blank\">launches </a>its generic version of Merck's CANCIDAS (caspofungin acetate), an antifungal with multiple indications.</li><li>According to IMS, the U.S. market is ~$24M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298769\" data-linked=\"Mylan launches generic version of Merck&#39;s Cancidas antifungal; shares ahead 2%\" data-tweet=\"$MYL - Mylan launches generic version of Merck&#39;s Cancidas antifungal; shares ahead 2% https://seekingalpha.com/news/3298769-mylan-launches-generic-version-of-mercks-cancidas-antifungal-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3298769-mylan-launches-generic-version-of-mercks-cancidas-antifungal-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298768\" data-ts=\"1506964121\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298768-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SAMG' title='Silvercrest Asset Management Group'>SAMG</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MTR' title='Mesa Royalty Trust'>MTR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FNF' title='Fidelity National Financial Inc.'>FNF</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298768\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$JP $SAMG $MHLD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3298768-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298768-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298764\" data-ts=\"1506963776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBS\" target=\"_blank\">EBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298764-emergent-bio-secures-200m-credit-facility-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emergent Bio secures $200M credit facility; shares up 1%</a></h4><ul><li>Emergent BioSolutions (<a href='https://seekingalpha.com/symbol/EBS' title='Emergent BioSolutions Inc.'>EBS</a> <font color='green'>+1.2%</font>) <a href=\"https://seekingalpha.com/pr/16955921-emergent-biosolutions-announces-closing-new-200-million-senior-secured-credit-facility\" target=\"_blank\">closes </a>a new five-year $200M syndicated senior credit facility, double its previous facility. The new deal includes a $100M accordion feature which could expand the total commitments up to $300M with an additional $100M in revolver or incremental term loans, at the company's option, subject to conditions.</li><li>The company says it will not tap the facility to pay for its previously announced acquisitions of raxibacumab from GlaxoSmithKline and ACAM2000 (smallpox vaccine) from Sanofi.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298764\" data-linked=\"Emergent Bio secures $200M credit facility; shares up 1%\" data-tweet=\"$EBS - Emergent Bio secures $200M credit facility; shares up 1% https://seekingalpha.com/news/3298764-emergent-bio-secures-200m-credit-facility-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3298764-emergent-bio-secures-200m-credit-facility-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298766\" data-ts=\"1506963767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298766-general-motors-ramps-up-all-electric-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Motors ramps up all-electric push</a></h4><ul> <li>General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) says it will <a href=\"http://www.gm.com/mol/m-2017-oct-1002-electric.html\" target=\"_blank\">introduce</a> two new all-electric models derived from the Chevrolet Bolt EV within 18 months.</li> <li>The company has a long range plan to unveil 20 different all-electric models by 2023.</li> <li>\"General Motors believes in an all-electric future,\" says product development boss Mark Reuss.</li> <li>\"Although that future won't happen overnight, GM is committed to driving increased usage and acceptance of electric vehicles through no-compromise solutions that meet our customers' needs,\" he adds.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298699-gm-plus-4-percent-buzz-autonomous-vehicle-program\" target=\"_blank\">GM +4% on buzz over autonomous vehicle program</a> (Oct. 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298766\" data-linked=\"General Motors ramps up all-electric push\" data-tweet=\"$GM - General Motors ramps up all-electric push https://seekingalpha.com/news/3298766-general-motors-ramps-up-all-electric-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3298766-general-motors-ramps-up-all-electric-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298763\" data-ts=\"1506963590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WNDW\" target=\"_blank\">WNDW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298763-solarwinds-gets-2_6m-via-private-placement-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SolarWinds gets $2.6M via private placement financing</a></h4><ul>     <li>SolarWindow Technologies (<a href='https://seekingalpha.com/symbol/WNDW' title='SolarWindow Technologies, Inc.'>OTCPK:WNDW</a> <font color='green'>+4.3%</font>) says it completed a <a href=\"https://seekingalpha.com/pr/16956213-solarwindow-completes-financing-advance-manufacturing-marketing-product-fabrication\" target=\"_blank\">private placement financing</a> for the purchase and sale of 821.6K units at $3.11 each for nearly $2.6M in proceeds.</li>     <li>WNDW says it plans to use the proceeds for general working capital purposes, including the further advancement of its previously announced manufacturing, marketing and product fabrication initiatives for its electricity-generating glass products for commercial buildings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298763\" data-linked=\"SolarWinds gets $2.6M via private placement financing\" data-tweet=\"$WNDW - SolarWinds gets $2.6M via private placement financing https://seekingalpha.com/news/3298763-solarwinds-gets-2_6m-via-private-placement-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3298763-solarwinds-gets-2_6m-via-private-placement-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298752\" data-ts=\"1506963160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABLYF\" target=\"_blank\">ABLYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298752-ablynxs-caplacizumab-successful-in-late-stage-study-in-rare-blood-disorder-shares-ahead-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ablynx&#39;s caplacizumab successful in late-stage study in rare blood disorder; shares ahead 24%</a></h4><ul><li>Thinly traded Ablynx (<a href='https://seekingalpha.com/symbol/ABLYF' title='Ablynx NV'>OTCPK:ABLYF</a> <font color='green'>+23.5%</font>) heads north on a healthy 29x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16955741-ablynx-announces-positive-topline-results-phase-iii-hercules-study-caplacizumab-treatment\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, HERCULES, assessing caplacizumab for the treatment of <a href=\"https://www.nhlbi.nih.gov/health/health-topics/topics/ttp\" target=\"_blank\">acquired thrombotic thrombocytopenic purpura</a> (aTTP), a rare blood disorder characterized by the formation of blood clots in small blood vessels.</li><li>The study met its primary endpoint and key secondary endpoints. Patients in the treatment group experienced a 74% reduction in the risk of aTTP-related death, recurrence of aTTP or at least one major thromboembolic event during the study period (p&lt;0.0001) compared to placebo. The proportion of patients whose aTTP recurred during the treatment period was 67% lower in the caplacizumab arm compared to the control arm (p&lt;0.001).</li><li>Caplacizumab's safety profile was consistent with earlier studies. One patient in the treatment arm died during the follow-up period, but the death was determined to be unrelated to the study drug.</li><li>Orphan Drug-tagged caplacizumab is a bivalent anti-von Willebrand (vWF) factor Nanobody that blocks the interaction of ultra-large vWF proteins with platelets which inhibits the formation of microclots.</li><li>The company's marketing application in Europe is currently under review. A U.S. application is on tap for next year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3281341-fda-fast-tracks-ablynxs-caplacizumab-rare-blood-disorder\" target=\"_blank\">FDA Fast Tracks Ablynx's caplacizumab for rare blood disorder</a> (July 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298752\" data-linked=\"Ablynx&#39;s caplacizumab successful in late-stage study in rare blood disorder; shares ahead 24%\" data-tweet=\"$ABLYF - Ablynx&#39;s caplacizumab successful in late-stage study in rare blood disorder; shares ahead 24% https://seekingalpha.com/news/3298752-ablynxs-caplacizumab-successful-in-late-stage-study-in-rare-blood-disorder-shares-ahead-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3298752-ablynxs-caplacizumab-successful-in-late-stage-study-in-rare-blood-disorder-shares-ahead-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298756\" data-ts=\"1506962336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298756-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+82%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/QTRH' title='Quarterhill Inc.'>QTRH</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='red'>-60%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/FNF' title='Fidelity National Financial Inc.'>FNF</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298756\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ECYT $VHC $CATB - Midday Gainers / Losers https://seekingalpha.com/news/3298756-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298756-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298755\" data-ts=\"1506962245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298755-micron-hits-new-heights-on-keybanc-dram-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron hits new heights on KeyBanc DRAM optimism</a></h4><ul><li>        Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) shares are&nbsp;<font color='green'>up 1.08%</font>&nbsp;and hit a 16-year high after <a href=\"http://www.marketwatch.com/story/microns-stock-rises-to-16-year-high-on-heavy-volume-after-upbeat-analyst-note-2017-10-02\" target=\"_blank\">comments</a> from KeyBanc analyst Weston Twigg.</li><li>               Twigg expects DRAM contract price increases to continue through year&rsquo;s end and views &ldquo;this trend as relatively positive for Micron.&rdquo;&nbsp;</li><li>               DRAM accounts for about two-thirds of Micron revenue. The company typically comes in <a href=\"https://www.statista.com/statistics/271725/global-dram-revenues-of-semiconductor-companies-since-2010/\" target=\"_blank\">third</a> in worldwide DRAM sales behind Samsung and SK Hynix.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298023-stocks-stage-broad-advance-paced-financials-techs\" target=\"_blank\">Stocks stage broad advance paced by financials, techs</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298755\" data-linked=\"Micron hits new heights on KeyBanc DRAM optimism\" data-tweet=\"$MU - Micron hits new heights on KeyBanc DRAM optimism https://seekingalpha.com/news/3298755-micron-hits-new-heights-on-keybanc-dram-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3298755-micron-hits-new-heights-on-keybanc-dram-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298744\" data-ts=\"1506960824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298744-options-activity-on-seaworld-entertainment-picks-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Options activity on SeaWorld Entertainment picks up</a></h4><ul> <li>SeaWorld Entertainment (<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a> <font color='green'>+2.6%</font>) jumps on a notable level of call buying going on in the background.</li> <li>Bloomberg reports that call volume on SeaWorld is 2.4X the 20-day average.</li> <li>The theme park operator isn't due to report earnings until the middle part of November.</li> <li>Shares of SeaWorld haven't been above $14 since early August.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298744\" data-linked=\"Options activity on SeaWorld Entertainment picks up\" data-tweet=\"$SEAS - Options activity on SeaWorld Entertainment picks up https://seekingalpha.com/news/3298744-options-activity-on-seaworld-entertainment-picks-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3298744-options-activity-on-seaworld-entertainment-picks-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298738\" data-ts=\"1506960053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298738-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='red'>-60%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298738\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KNDI $LFVN $CLXT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3298738-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298738-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298734\" data-ts=\"1506959443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBS\" target=\"_blank\">CBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298734-cbs-gray-television-set-multi-year-affiliation-renewal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBS, Gray Television set multi-year affiliation renewal</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='green'>+0.9%</font>) has reached a new <a href=\"https://seekingalpha.com/pr/16956659-cbs-gray-television-renew-affiliations-grays-cbs-stations-nationwide\" target=\"_blank\">multi-year station affiliation renewal</a> with Gray Television (<a href=\"http://seekingalpha.com/symbol/GTN\" target=\"_blank\">GTN</a> <font color='green'>+2.2%</font>), one of the country's largest local broadcasters.</li>    <li>The deal covers Gray's 39 CBS affiliates across 32 Nielsen markets.</li>    <li>Most of the Gray CBS stations are No. 1 in their markets, CBS notes, and have been CBS affiliates for five decades or more.</li>    <li>The Gray markets collectively include about 5.9M TV households.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298734\" data-linked=\"CBS, Gray Television set multi-year affiliation renewal\" data-tweet=\"$CBS $VIAC $GTN - CBS, Gray Television set multi-year affiliation renewal https://seekingalpha.com/news/3298734-cbs-gray-television-set-multi-year-affiliation-renewal?source=tweet\" data-url=\"https://seekingalpha.com/news/3298734-cbs-gray-television-set-multi-year-affiliation-renewal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298733\" data-ts=\"1506958740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCFT\" target=\"_blank\">MCFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298733-boating-stocks-up-amid-m-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boating stocks up amid M&amp;A focus</a></h4><ul>      <li>The acquisition by MasterCraft (<a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a> <font color='green'>+3.4%</font>) of NauticStar in ~$79.8M deal has investors looking at the boating sector with renewed interest.</li>     <li>Malibu Boats (<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a> <font color='green'>+3.1%</font>), MarineMax (<a href='https://seekingalpha.com/symbol/HZO' title='MarineMax Inc.'>HZO</a> <font color='green'>+0.6%</font>) and Brunswick (<a href='https://seekingalpha.com/symbol/BC' title='Brunswick Corporation'>BC</a> <font color='green'>+1.7%</font>) are all higher on the day.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16956261-mastercraft-acquires-nauticstar-llc\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298733\" data-linked=\"Boating stocks up amid M&amp;A focus\" data-tweet=\"$MCFT $MCFT $MBUU - Boating stocks up amid M&amp;A focus https://seekingalpha.com/news/3298733-boating-stocks-up-amid-m-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/3298733-boating-stocks-up-amid-m-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298731\" data-ts=\"1506958525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298731-tech-stocks-moving-on-analyst-actions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech stocks moving on analyst actions</a></h4><ul><li>        KeyBanc <a href=\"http://timesofindia.indiatimes.com/business/international-business/parker-hannifin-pepsico-priceline-group/articleshow/60913036.cms\" target=\"_blank\">upgrades</a> Cavium (CAVM) from Sector Weight to Overweight. Cavium shares are&nbsp;<font color='green'>up 4.38%</font>.</li><li>               Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) shares are&nbsp;<font color='green'>up 3.08%</font>&nbsp;after Craig-Hallum <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/17/10/10125151/benzingas-top-upgrades-downgrades-for-october-2-2017\" target=\"_blank\">upgrades</a> the stock from Hold to Buy.&nbsp;</li><li>               Shares of eGain (NASDAQ:<a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a>) are&nbsp;<font color='green'>up 9.26%</font>&nbsp;on a Craig-Hallum <a href=\"https://www.streetinsider.com/Analyst+Comments/Craig-Hallum+Upgrades+eGain+Corporation+%28EGAN%29+to+Buy/13347629.html\" target=\"_blank\">upgrade</a> to Buy with a $4 price target.&nbsp;</li><li>               Cowen <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Cowen+Downgrades+Appian+Corp.+%28APPN%29+to+Market+Perform/13346883.html\" target=\"_blank\">downgrades</a> Appian (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a>) from Outperform to Market Perform. Shares are&nbsp;<font color='red'>down 9.52%</font>.&nbsp;</li><li>               Northcoast <a href=\"https://thefly.com/landingPageNews.php?id=2616943&amp;headline=SCSC-Scansource-rating-change-\" target=\"_blank\">downgrades</a> ScanSource (NASDAQ:<a href='https://seekingalpha.com/symbol/SCSC' title='ScanSource, Inc.'>SCSC</a>) from Buy to Neutral. ScanSource shares are&nbsp;<font color='red'>down 1.26%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298731\" data-linked=\"Tech stocks moving on analyst actions\" data-tweet=\"$MRVL $MRVL $STX - Tech stocks moving on analyst actions https://seekingalpha.com/news/3298731-tech-stocks-moving-on-analyst-actions?source=tweet\" data-url=\"https://seekingalpha.com/news/3298731-tech-stocks-moving-on-analyst-actions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298729\" data-ts=\"1506958412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298729-good-day-for-dollar-in-store-says-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Good day for the dollar; more in store, says Goldman</a></h4><ul><li>The dollar index (<a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='PowerShares DB USD Bear ETF'>UDN</a>) is<font color='green'> higher by 0.6%</font>&nbsp;on the session. It's been on rise since trading started on Sunday evening, and added to gains after stronger-than-expected prints on U.S. manufacturing and construction spending.</li><li>A team at Goldman - noting futures markets pricing in little more than one rate hike between now and the end of 2018 - <a href=\"https://www.ft.com/content/dc41538d-71b2-30d2-92f3-5e028572619d\" target=\"_blank\">says markets are being </a>much too conservative, particularly with a sizable tax cut looking like it may be on the way.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298729\" data-linked=\"Good day for the dollar; more in store, says Goldman\" data-tweet=\"$UUP $UDN - Good day for the dollar; more in store, says Goldman https://seekingalpha.com/news/3298729-good-day-for-dollar-in-store-says-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3298729-good-day-for-dollar-in-store-says-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298728\" data-ts=\"1506958134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298728-fda-oks-lannetts-generic-prevacid-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Lannett&#39;s generic Prevacid; shares ahead 8%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16955883-lannett-receives-two-fda-approvals-lansoprazole-delayed-release-capsules-usp-one-full\" target=\"_blank\">approves </a>Lannett Company's (<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='green'>+7.6%</font>) marketing applications for Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg, its generic version of Takeda Pharmaceutical's Prevacid Delayed-Release Capsules, 15 mg and 30 mg and an over-the-counter 15 mg version, the generic equivalent to GlaxoSmithKline's Prevacid 24 HR Delayed-Release Capsules, 15 mg.</li><li>According to IMS, the U.S. market is ~$76M.</li><li>Market launch will commence in the coming months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298728\" data-linked=\"FDA OKs Lannett&#39;s generic Prevacid; shares ahead 8%\" data-tweet=\"$LCI - FDA OKs Lannett&#39;s generic Prevacid; shares ahead 8% https://seekingalpha.com/news/3298728-fda-oks-lannetts-generic-prevacid-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3298728-fda-oks-lannetts-generic-prevacid-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298727\" data-ts=\"1506957603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298727-time-launches-300m-private-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time launches $300M private debt offering</a></h4><ul>   <li>Time Inc. (<a href=\"http://seekingalpha.com/symbol/TIME\" target=\"_blank\">TIME</a> <font color='green'>+1.9%</font>) has launched a <a href=\"https://seekingalpha.com/pr/16956006-time-inc-announces-launch-senior-notes-offering\" target=\"_blank\">private offering of $300M</a> in senior debt.</li>    <li>Net proceeds from the senior notes will be used to repay about $200M of borrowings under its senior secured term loan facility, with about another $100M going to some combination of term loan facility and the company's outstanding 5.75% senior notes due 2022.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298727\" data-linked=\"Time launches $300M private debt offering\" data-tweet=\"$MDP - Time launches $300M private debt offering https://seekingalpha.com/news/3298727-time-launches-300m-private-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3298727-time-launches-300m-private-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298725\" data-ts=\"1506957378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298725-community-health-completes-sale-of-texas-hospital-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Health completes sale of Texas hospital; shares up 1%</a></h4><ul><li>Community Health Systems (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+0.7%</font>) <a href=\"https://seekingalpha.com/pr/16955887-community-health-systems-completes-divestiture-weatherford-texas-hospital\" target=\"_blank\">completes </a>the sale of the 103-bed Weatherford Regional Medical Center in Weatherford, TX, one of the 30 planned divestitures the company discussed in its Q2 earnings call.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298725\" data-linked=\"Community Health completes sale of Texas hospital; shares up 1%\" data-tweet=\"$CYH - Community Health completes sale of Texas hospital; shares up 1% https://seekingalpha.com/news/3298725-community-health-completes-sale-of-texas-hospital-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3298725-community-health-completes-sale-of-texas-hospital-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298722\" data-ts=\"1506957150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298722-redhill-cuts-enrollment-in-late-stage-study-of-rhbminus-104-in-crohns-topline-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill cuts enrollment in late-stage study of RHB-104 in Crohn&#39;s, topline results expected mid-2018; shares ahead 3%</a></h4><ul><li>Confident that its has <a href=\"https://seekingalpha.com/pr/16955950-redhill-biopharma-accelerates-rhbminus-104-phase-iii-study-crohn-s-disease-top-line-results\" target=\"_blank\">sufficient enrollment</a> to demonstrate efficacy, RedHill Biopharma (<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='green'>+3.1%</font>) cuts the target to 325 from 410 in its Phase 3 clinical trial, MAP US, assessing RHB-104 in patients with moderately to severely active Crohn's disease.</li><li>Current enrollment stands at 322 so achieving the lowered target of 325 should be done by next month. Topline data are expected in mid-2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278151-redhill-updates-crohns-candidate-rhbminus-104-second-dsmb-review-later-month\" target=\"_blank\">RedHill updates on Crohn's candidate RHB-104, second DSMB review later this month</a> (July 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298722\" data-linked=\"RedHill cuts enrollment in late-stage study of RHB-104 in Crohn&#39;s, topline results expected mid-2018; shares ahead 3%\" data-tweet=\"$RDHL - RedHill cuts enrollment in late-stage study of RHB-104 in Crohn&#39;s, topline results expected mid-2018; shares ahead 3% https://seekingalpha.com/news/3298722-redhill-cuts-enrollment-in-late-stage-study-of-rhbminus-104-in-crohns-topline-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3298722-redhill-cuts-enrollment-in-late-stage-study-of-rhbminus-104-in-crohns-topline-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298721\" data-ts=\"1506957063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUE\" target=\"_blank\">TRUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298721-morgan-stanley-upgrades-truecar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley upgrades TrueCar</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Upgrades+TrueCar+%28TRUE%29+to+Equalweight/13346716.html\" target=\"_blank\">upgrades</a> TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc'>TRUE</a>) to Equal Weight from Underweight with a $13 price target.</li><li>                  Analyst Brian Nowak sees a fair risk-reward balance but calls the company one of the most expensive names he covers due to its 30x 2018 estimated EBITDA.    </li><li>               TrueCar shares are&nbsp;<font color='red'>down 0.66%</font>&nbsp;to $15.68. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298721\" data-linked=\"Morgan Stanley upgrades TrueCar\" data-tweet=\"$TRUE - Morgan Stanley upgrades TrueCar https://seekingalpha.com/news/3298721-morgan-stanley-upgrades-truecar?source=tweet\" data-url=\"https://seekingalpha.com/news/3298721-morgan-stanley-upgrades-truecar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298720\" data-ts=\"1506957006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLF\" target=\"_blank\">CLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298720-cleveland-cliffs-buys-remaining-tilden-mine-interest-for-105m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland-Cliffs buys remaining Tilden Mine interest for $105M</a></h4><ul>     <li>Cleveland-Cliffs (<a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+2.7%</font>) <a href=\"https://seekingalpha.com/pr/16955896-cleveland-cliffs-inc-announces-acquisition-remaining-equity-interest-tilden-mine\" target=\"_blank\">agrees to acquire</a> U.S. Steel's (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+1.2%</font>) 15% equity interest in the Tilden Mine for $105M; CLF already owned 85% of the joint venture.</li>     <li>With the additional capacity, CLF forecasts pellet sales volume in its U.S. Iron Ore segment will increase to 20M long tons in  2018 from an expected 19M long tons in 2017.</li>     <li>Tilden is a Michigan-based iron ore mining, concentrating, pelletizing and railroad operation with ~900 employees.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298720\" data-linked=\"Cleveland-Cliffs buys remaining Tilden Mine interest for $105M\" data-tweet=\"$CLF $CLF $X - Cleveland-Cliffs buys remaining Tilden Mine interest for $105M https://seekingalpha.com/news/3298720-cleveland-cliffs-buys-remaining-tilden-mine-interest-for-105m?source=tweet\" data-url=\"https://seekingalpha.com/news/3298720-cleveland-cliffs-buys-remaining-tilden-mine-interest-for-105m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298718\" data-ts=\"1506956687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTXS\" target=\"_blank\">CTXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298718-wells-fargo-upgrades-citrix-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo upgrades Citrix Systems</a></h4><ul><li>        Wells Fargo <a href=\"https://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Upgrades+Citrix+Systems+%28CTXS%29+to+Outperform/13346762.html\" target=\"_blank\">upgrades</a> Citrix Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CTXS' title='Citrix Systems, Inc.'>CTXS</a>) from Market Perform to Outperform and raises the price target from $82.50 to $95.</li><li>               Analyst Philip Winslow thinks the Street underestimates the impact from forced migration to Customer Success Services and says the company could drive buybacks through increased balance sheet leveraging.&nbsp;</li><li>               Winslow notes that Citrix currently trades near its lowest cash flow multiple since 2008.&nbsp;&nbsp;</li><li>Citrix Systems shares are&nbsp;<font color='green'>up 4.76%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298718\" data-linked=\"Wells Fargo upgrades Citrix Systems\" data-tweet=\"$CTXS - Wells Fargo upgrades Citrix Systems https://seekingalpha.com/news/3298718-wells-fargo-upgrades-citrix-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3298718-wells-fargo-upgrades-citrix-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298715\" data-ts=\"1506956444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298715-healthcare-top-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298715\" data-linked=\"Healthcare - Top Gainers / Losers as of 11:00 am\" data-tweet=\"$ECYT $RIGL $CAPR - Healthcare - Top Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3298715-healthcare-top-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3298715-healthcare-top-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298714\" data-ts=\"1506956364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATEC\" target=\"_blank\">ATEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298714-alphatec-adds-two-industry-veterans-to-leadership-agree-to-invest-3_5m-shares-ahead-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alphatec adds two industry veterans to leadership, agree to invest $3.5M; shares ahead 16%</a></h4><ul><li>Thinly traded nano cap Alphatec Holdings (<a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a> <font color='green'>+16.3%</font>) is up on a 4x surge in volume, albeit on turnover of only 362K shares, in response to the <a href=\"https://seekingalpha.com/pr/16956420-alphatec-accelerates-business-transformation-additional-spine-experienced-leadership\" target=\"_blank\">news </a>that Patrick MIles has been appointed Executive Chairman and Quentin Blackford as a board member. The two industry veterans will invest $3.5M in the company.</li><li>Mr. Miles served at NuVasive for 17 years, most recently as Vice Chairman.</li><li>Mr. Blackford is currently EVP and CFO at DexCom. Before that, he was EVP and CFO, Head of Strategy and Corporate Integrity at NuVasive.</li><li>CEO Terry Rich will continue in his role and will report to Miles.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298714\" data-linked=\"Alphatec adds two industry veterans to leadership, agree to invest $3.5M; shares ahead 16%\" data-tweet=\"$ATEC - Alphatec adds two industry veterans to leadership, agree to invest $3.5M; shares ahead 16% https://seekingalpha.com/news/3298714-alphatec-adds-two-industry-veterans-to-leadership-agree-to-invest-3_5m-shares-ahead-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3298714-alphatec-adds-two-industry-veterans-to-leadership-agree-to-invest-3_5m-shares-ahead-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298713\" data-ts=\"1506956032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298713-synchronoss-shares-soar-on-strategic-transaction-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss shares soar on strategic transaction talks</a></h4><ul><li>        Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) shares are&nbsp;<font color='green'>up 18%&nbsp;</font>after <a href=\"https://seekingalpha.com/pr/16955609-synchronoss-technologies-issues-statement-regarding-strategic-alternatives-process\" target=\"_blank\">announcing</a> that the company &ldquo;remains in active discussions with multiple parties&rdquo; regarding strategic transactions.</li><li>               The company opted not to offer exclusivity to Siris, which ended the talks between the companies.&nbsp;</li><li>               Company statement: &ldquo;Synchronoss&rsquo; Board of Directors continues to be committed to enhancing value for all shareholders. The Board&rsquo;s strategic alternatives process remains underway and it continues to explore a full range of strategic, operational and financial alternatives.&rdquo;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298713\" data-linked=\"Synchronoss shares soar on strategic transaction talks\" data-tweet=\"$SNCR - Synchronoss shares soar on strategic transaction talks https://seekingalpha.com/news/3298713-synchronoss-shares-soar-on-strategic-transaction-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3298713-synchronoss-shares-soar-on-strategic-transaction-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298712\" data-ts=\"1506955949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGG-OLD\" target=\"_blank\">CGG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298712-cgg-wins-creditor-support-for-chapter-11-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CGG wins creditor support for Chapter 11 plan</a></h4><ul>     <li>CGG&nbsp;(<a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-7%</font>) says its bondholers have <a href=\"https://globenewswire.com/news-release/2017/10/02/1138471/0/en/CGG-announces-overwhelming-acceptance-by-creditors-entitled-to-vote-on-the-chapter-11-plan.html\" target=\"_blank\">approved its Chapter 11 bankruptcy plan</a>, after filing for bankruptcy in France and the U.S. in June as part of a restructuring.</li>     <li>CGG is burdened with more than $3B of debt, and the restructuring calls for unsecured debt to be converted to equity, maturities on secured debt to be extended and $500M in new money to be raised.</li>     <li>CGG, which specializes in geo-seismic surveys, <a href=\"https://www.reuters.com/article/cgg-restructuring/creditors-accept-restructuring-plan-for-oil-services-group-cgg-idUSFWN1MD00Q\" target=\"_blank\">struggled</a> to keep up with debt payments as oil companies that use its services trimmed exploration spending.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298712\" data-linked=\"CGG wins creditor support for Chapter 11 plan\" data-tweet=\"$CGG-OLD - CGG wins creditor support for Chapter 11 plan https://seekingalpha.com/news/3298712-cgg-wins-creditor-support-for-chapter-11-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3298712-cgg-wins-creditor-support-for-chapter-11-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298710\" data-ts=\"1506955411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298710-med-stocks-up-early-biotechs-lead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Med stocks up early, biotechs lead</a></h4><ul><li>Biotech, biopharma and medical device stocks show positive action in early trading, leading the broad market rally.</li><li>(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='green'>+2.9%</font>)(<a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a> <font color='green'>+2.3%</font>)(<a href='https://seekingalpha.com/symbol/BBC' title='BioShares Biotechnology Clinical Trials ETF'>BBC</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/GNRX' title='VanEck Vectors Generic Drugs ETF'>GNRX</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/FTXH' title='First Trust Nasdaq Pharmaceuticals ETF'>FTXH</a>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+2.2%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='red'>-0.1%</font>)(<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+0.1%</font>)(<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color='green'>+0.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298710\" data-linked=\"Med stocks up early, biotechs lead\" data-tweet=\"$GILD $IBB $XBI - Med stocks up early, biotechs lead https://seekingalpha.com/news/3298710-med-stocks-up-early-biotechs-lead?source=tweet\" data-url=\"https://seekingalpha.com/news/3298710-med-stocks-up-early-biotechs-lead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298706\" data-ts=\"1506954902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMTX\" target=\"_blank\">DMTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298706-dimension-therapeutics-backs-ultragenyx-pharmas-6-share-bid-loser-regenxbio-to-get-2_85m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dimension Therapeutics backs Ultragenyx Pharma&#39;s $6/share bid, loser REGENXBIO to get $2.85M termination fee</a></h4><ul><li>The board of Dimension Therapeutics (<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-1.7%</font>) has <a href=\"https://seekingalpha.com/pr/16956109-dimension-board-determines-ultragenyx-s-unsolicited-proposal-acquire-dimension-6_00-per-share\" target=\"_blank\">determined </a>that the $6/share offer by Ultragenyx Pharmaceutical (<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color='green'>+2.8%</font>) is a \"Superior Proposal\" per its merger agreement with REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>), allowing it to accept RARE's bid.</li><li>Under the terms of the agreement, REGENXBIO will receive a termination fee of $2.85M that RARE has agreed to pay on Dimension's behalf.</li><li>In a <a href=\"https://seekingalpha.com/pr/16956254-regenxbio-responds-notification-superior-proposal-merger-agreement-dimension-therapeutics\" target=\"_blank\">statement</a>, REGENXBIO says its all-stock deal, with an implied value of $3.41/share, reflects fair value so it will not counter with a higher offer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298706\" data-linked=\"Dimension Therapeutics backs Ultragenyx Pharma&#39;s $6/share bid, loser REGENXBIO to get $2.85M termination fee\" data-tweet=\"$DMTX $DMTX $RARE - Dimension Therapeutics backs Ultragenyx Pharma&#39;s $6/share bid, loser REGENXBIO to get $2.85M termination fee https://seekingalpha.com/news/3298706-dimension-therapeutics-backs-ultragenyx-pharmas-6-share-bid-loser-regenxbio-to-get-2_85m?source=tweet\" data-url=\"https://seekingalpha.com/news/3298706-dimension-therapeutics-backs-ultragenyx-pharmas-6-share-bid-loser-regenxbio-to-get-2_85m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298705\" data-ts=\"1506954435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298705-breakout-extends-for-kandi-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Breakout extends for Kandi Technologies</a></h4><ul> <li>Shares of Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) blasts past the $6 threshold with a <font color='green'>rally of 11.29%</font> this morning on strong volume.</li> <li>It's the first time Kandi has traded over $6 since last October.</li> <li>There was quite a bit of EV news out of China last week that could still be on the radar of investors.</li><li><a href=\"https://seekingalpha.com/pr/16955092-b-kandi-b-jv-company-expands-efforts-attract-renewable-energy-industry-talent\" target=\"_blank\">Kandi press release on renewable energy initiative</a></li><li><a href=\"https://seekingalpha.com/news/3298201-china-sets-electric-vehicles-policy\" target=\"_blank\">China sets electric vehicles policy</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298705\" data-linked=\"Breakout extends for Kandi Technologies\" data-tweet=\"$KNDI - Breakout extends for Kandi Technologies https://seekingalpha.com/news/3298705-breakout-extends-for-kandi-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3298705-breakout-extends-for-kandi-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298702\" data-ts=\"1506953993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298702-fda-ad-com-review-october-18-for-novos-semaglutide-for-t2d-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com review October 18 for Novo&#39;s semaglutide for T2D; shares ahead 2%</a></h4><ul><li>The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will <a href=\"https://s3.amazonaws.com/public-inspection.federalregister.gov/2017-21176.pdf\" target=\"_blank\">meet</a> on October 18 to review and discuss Novo Nordisk's (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='green'>+1.7%</font>) New Drug Application &#40;NDA&#41; seeking approval for semaglutide injection for the treatment of adults with type 2 diabetes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289935-novos-semaglutide-beats-lillys-dulaglutide-late-stage-study-type-2-diabetics-shares-ahead-3\" target=\"_blank\">Novo's semaglutide beats Lilly's dulaglutide in late-stage study in type 2 diabetics; shares ahead 3%</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298702\" data-linked=\"FDA Ad Com review October 18 for Novo&#39;s semaglutide for T2D; shares ahead 2%\" data-tweet=\"$NVO - FDA Ad Com review October 18 for Novo&#39;s semaglutide for T2D; shares ahead 2% https://seekingalpha.com/news/3298702-fda-ad-com-review-october-18-for-novos-semaglutide-for-t2d-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3298702-fda-ad-com-review-october-18-for-novos-semaglutide-for-t2d-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298701\" data-ts=\"1506953555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298701-allergan-files-u-s-marketing-application-for-expanded-use-of-avycaz-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan files U.S. marketing application for expanded use of Avycaz; shares up 2%</a></h4><ul><li>Allergan plc (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+2.1%</font>) files a supplemental New Drug Application (sNDA) with the FDA <a href=\"https://seekingalpha.com/pr/16956086-fda-accepts-supplemental-new-drug-application-snda-filing-avycaz-ceftazidime-avibactam\" target=\"_blank\">seeking approval</a> to use AVYCAZ (ceftazidime and avibactam) to treat adults with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, a Priority Review and QIDP indication.</li><li>The agency's action should be in Q1 2018.</li><li><a href=\"https://www.avycaz.com/\" target=\"_blank\">AVYCAZ </a>is currently approved to treat complicated intra-abdominal infections and complicated urinary tract infections.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298701\" data-linked=\"Allergan files U.S. marketing application for expanded use of Avycaz; shares up 2%\" data-tweet=\"$AGN - Allergan files U.S. marketing application for expanded use of Avycaz; shares up 2% https://seekingalpha.com/news/3298701-allergan-files-u-s-marketing-application-for-expanded-use-of-avycaz-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3298701-allergan-files-u-s-marketing-application-for-expanded-use-of-avycaz-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298699\" data-ts=\"1506953471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298699-gmplus-4-on-buzz-over-autonomous-vehicle-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM +4% on buzz over autonomous vehicle program</a></h4><ul> <li>Deutsche Bank doubles down on its bullish view of General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) in a new note to clients that highlights the huge upside potential from the expanding autonomous vehicle program.</li> <li>The investment firm expects autonomous vehicles to be rolled out much sooner than expected and sees GM as well-positioned to benefit.</li> <li>On an interesting note for shareholders, DB says GM management didn't refute the logic of a mobility business spinoff.</li> <li>Analyst Rod Lache and team have an official price target of $51 on GM, but see the potential for long-terms gains beyond that mark.</li><li>Though DB's actual upgrade on GM was last week, shares of GM are&nbsp;<font color='green'>up 4.41%&nbsp;</font>this morning because today's refresher note follows a meeting with GM management.</li>  <li>Sources: Bloomberg and <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">NotableCalls</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298699\" data-linked=\"GM +4% on buzz over autonomous vehicle program\" data-tweet=\"$GM - GM +4% on buzz over autonomous vehicle program https://seekingalpha.com/news/3298699-gmplus-4-on-buzz-over-autonomous-vehicle-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3298699-gmplus-4-on-buzz-over-autonomous-vehicle-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298690\" data-ts=\"1506952978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYBE\" target=\"_blank\">CYBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298690-cyberoptics-shares-plunge-after-lowering-q3-revenue-estimate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CyberOptics shares plunge after lowering Q3 revenue estimate</a></h4><ul><li>        CyberOptics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a>) shares are&nbsp;<font color='red'>down 25.62%</font>&nbsp;after the company <a href=\"https://seekingalpha.com/pr/16956223-cyberoptics-revises-third-quarter-revenue-guidance-provides-initial-fourth-quarter-forecast\" target=\"_blank\">revises</a> its Q3 guidance and provides a Q4 forecast.</li><li>               Q3 revenue drops to the range of $11.6M to $11.8M from $13M to $15M. Lower revenue due to a delayed $1M order that was only partially recognized in the third quarter and lower than expected sales.&nbsp;</li><li>               Q4 outlook has revenue between $11.5M and $13M.&nbsp;</li><li>               CyberOptics will report Q3 earnings on October 24.&nbsp;</li><li>               CyberOptics also <a href=\"https://seekingalpha.com/pr/16956210-cyberoptics-announces-3-million-share-repurchase-authorization\" target=\"_blank\">announces</a> a $3M share repurchase authorization.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298690\" data-linked=\"CyberOptics shares plunge after lowering Q3 revenue estimate\" data-tweet=\"$CYBE - CyberOptics shares plunge after lowering Q3 revenue estimate https://seekingalpha.com/news/3298690-cyberoptics-shares-plunge-after-lowering-q3-revenue-estimate?source=tweet\" data-url=\"https://seekingalpha.com/news/3298690-cyberoptics-shares-plunge-after-lowering-q3-revenue-estimate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298687\" data-ts=\"1506952799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298687-nordstrom-slides-on-report-of-go-private-obstacles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom slides on report of go-private obstacles</a></h4><ul> <li>Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) swings lower after New York Post <a href=\"http://nypost.com/2017/10/01/talks-to-take-nordstrom-private-are-faltering-sources/\" target=\"_blank\">reports</a> that efforts to pull together a go-private deal are faltering.</li> <li>Sources indicate that the Nordstrom family is having trouble lining up financing.</li> <li>Shares of Nordstrom are&nbsp;<font color='red'>down 6.60%</font>&nbsp;on heavy volume as the M&amp;A premium built up in the department stock gets pulled away.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298687\" data-linked=\"Nordstrom slides on report of go-private obstacles\" data-tweet=\"$JWN - Nordstrom slides on report of go-private obstacles https://seekingalpha.com/news/3298687-nordstrom-slides-on-report-of-go-private-obstacles?source=tweet\" data-url=\"https://seekingalpha.com/news/3298687-nordstrom-slides-on-report-of-go-private-obstacles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298682\" data-ts=\"1506952733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCRB\" target=\"_blank\">MCRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298682-early-stage-data-on-seres-therapeutics-serminus-287-in-uc-disappoints-investors-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage data on Seres Therapeutics&#39; SER-287 in UC disappoints investors, shares down 17%</a></h4><ul><li>Thinly traded Seres Therapeutics (<a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a> <font color='red'>-16.8%</font>)&nbsp;slumps out the gate this morning on investors' apparent disappoint with <a href=\"https://seekingalpha.com/pr/16955962-correcting-replacing-seres-therapeutics-reports-positive-topline-results-serminus-287-phase\" target=\"_blank\">Phase 1b results</a> for oral microbiome therapeutic candidate SER-287 in patients with mild-to-moderate ulcerative colitis &#40;UC&#41;.</li><li>The 58-subject study randomized participants into one of four arms: weekly SER-287 alone, weekly SER-287 with vancomycin pretreatment, daily SER-287 with vancomycin pretreatment or placebo. Primary endpoints were safety and tolerability while secondary endpoints included efficacy measures.</li><li>In terms of clinical remission &#40;CR&#41;, daily SER-287 + vanco pretreatment showed a 40% (n=6/15) CR rate compared to 10% (n=1/10) for placebo. CR rates for weekly SER-287/vanco and SER-287 alone (placebo pretreatment) were 21.4% (n=3/14) and 14.3% (n=2/14), respectively.</li><li>In term of clinical response, none of the three treatment arms beat placebo. The response rates for daily SER-287/vance and placebo were both 60.0%, ahead of 42.9% for weekly SER-287/placebo and 28.6% for weekly SER-287/vanco.</li><li>SER-287's safety profile was favorable.</li><li>The company says it intends to advance development of SER-287, a consortium of live bacterial spores, including Crohn's disease and pediatric forms of inflammatory bowel disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298682\" data-linked=\"Early-stage data on Seres Therapeutics&#39; SER-287 in UC disappoints investors, shares down 17%\" data-tweet=\"$MCRB - Early-stage data on Seres Therapeutics&#39; SER-287 in UC disappoints investors, shares down 17% https://seekingalpha.com/news/3298682-early-stage-data-on-seres-therapeutics-serminus-287-in-uc-disappoints-investors-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3298682-early-stage-data-on-seres-therapeutics-serminus-287-in-uc-disappoints-investors-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298678\" data-ts=\"1506950950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298678-virnetx-shares-up-33-on-potential-apple-case-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VirnetX shares up 33% on potential Apple case ruling</a></h4><ul><li>           VirnetX (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) shares are&nbsp;<font color='green'>up 33.33%&nbsp;</font>after <a href=\"https://twitter.com/TradeHawk/status/913936277761802240\" target=\"_blank\">tweets</a> suggesting that a final judgment in its court case with Apple was released but sealed until no later than October 13. </li><li>        VirnetX shares fell 17% last December after the U.S. Court of Appeals affirmed two patent invalidation rulings. &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290708-virnetx-htc-announce-patent-standstill-agreement\" target=\"_blank\">VirnetX, HTC announce patent standstill agreement</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298678\" data-linked=\"VirnetX shares up 33% on potential Apple case ruling\" data-tweet=\"$VHC - VirnetX shares up 33% on potential Apple case ruling https://seekingalpha.com/news/3298678-virnetx-shares-up-33-on-potential-apple-case-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3298678-virnetx-shares-up-33-on-potential-apple-case-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298677\" data-ts=\"1506950845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298677-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+31%</font>.</li><li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+20%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/pr/16955985-rigel-provides-update-fda-review-fostamatinib-itp\" target=\"_blank\">review</a> of fostamatinib for ITP.</li><li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16955609-synchronoss-technologies-issues-statement-regarding-strategic-alternatives-process\" target=\"_blank\">strategic</a> alternative process.</li><li><a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='green'>+16%</font>&nbsp;on late-stage <a href=\"https://seekingalpha.com/news/3298642-vbls-late-stage-study-vbminus-111-brain-cancer-continue-planned-topline-data-q1-2018-shares\" target=\"_blank\">study</a> of VB-111 in brain cancer to continue as planned.</li><li><a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298652-endocyte-licenses-late-stage-prostate-cancer-candidate-abx-gmbh-shares-ahead-11-percent\" target=\"_blank\">in-licenses</a> late-stage prostate cancer candidate from ABX GmbH.</li><li>ITUS <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16955824-itus-corporation-completes-market-offering\" target=\"_blank\">completion</a> of At-the-Market offering.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16956402-srax-acquires-opendsps-demand-side-platform\" target=\"_blank\">acquisition</a> of&nbsp; openDSP's demand-side platform.</li><li><a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a> <font color='green'>+11</font>&nbsp;on court <a href=\"https://seekingalpha.com/news/3298651-trinity-industries-soars-court-win\" target=\"_blank\">win</a>.</li><li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+9%&nbsp;</font>on Afrezza label <a href=\"https://seekingalpha.com/news/3298631-mannkind-ahead-9-percent-premarket-afrezza-label-update\" target=\"_blank\">update</a>.</li><li><a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16956348-veritone-expands-relationship-iheartmedia-now-provides-advanced-ai-solutions-200-broadcast\" target=\"_blank\">expanding</a> relationship with iHeartMedia.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corp'>ABUS</a> <font color='green'>+7%</font>&nbsp;on $116.4M capital <a href=\"https://seekingalpha.com/news/3298625-arbutus-inks-116_4m-capital-raise-shares-ahead-22-percent-premarket\" target=\"_blank\">raise</a>.</li><li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+7%</font>&nbsp;on&nbsp;mulling <a href=\"https://seekingalpha.com/news/3298611-dynavax-mulling-options-heplisav-b-shares-ahead-11-percent-premarket\" target=\"_blank\">options</a> with Heplisav-B.</li><li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298677\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$VHC $RIGL $SNCR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3298677-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298677-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298675\" data-ts=\"1506950403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298675-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) initiated with Buy rating and $10 (124% upside) by H.C. Wainwright.</li><li>Myriad Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a>) resumed with Market Perform rating and $31 (14% downside risk)&nbsp;by Leerink.</li><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) upgraded to Outperform by Leerink.</li><li>Repligen (NASDAQ:<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a>) upgraded to Overweight with a $47 (23% upside) price target by First Analysis.</li><li>Alnylam (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) upgraded to Buy by Goldman Sachs. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) downgraded to Underweight by Morgan Stanley citing headwinds facing NT sickle cell. Shares down&nbsp;<font color='red'>4%</font>&nbsp;premarket.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298675\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AGRX $AGRX $MYGN - Premarket analyst action - healthcare https://seekingalpha.com/news/3298675-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3298675-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298674\" data-ts=\"1506950221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298674-bofaml-analyst-says-oracle-rerate-like-microsoft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML analyst says Oracle could &quot;rerate&quot; like Microsoft</a></h4><ul><li>        Bank of America Merrill Lynch analyst Kash Rangan reiterates a Buy rating on Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) with a $62 price target.</li><li>               Rangan says the company has the potential to &ldquo;rerate&rdquo; like Microsoft with the apps business poised to grow around cloud adoption and the core DB becoming more defensible.&nbsp;</li><li>               The analyst expects Oracle&rsquo;s estimates of 60% SaaS and 30% PaaS/IaaS gross margins to prove conservative.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp;</li><li>Oracle shares are&nbsp;<font color='green'>up 0.72%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298674\" data-linked=\"BofAML analyst says Oracle could &quot;rerate&quot; like Microsoft\" data-tweet=\"$ORCL - BofAML analyst says Oracle could &quot;rerate&quot; like Microsoft https://seekingalpha.com/news/3298674-bofaml-analyst-says-oracle-rerate-like-microsoft?source=tweet\" data-url=\"https://seekingalpha.com/news/3298674-bofaml-analyst-says-oracle-rerate-like-microsoft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298671\" data-ts=\"1506949748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSI\" target=\"_blank\">VSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298671-vitamin-shoppe-higher-after-launching-digital-platform-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vitamin Shoppe higher after launching digital platform in China</a></h4><ul> <li>Vitamin Shoppe (NYSE:<a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a>) pops after the company announces the <a href=\"https://seekingalpha.com/pr/16956209-vitamin-shoppe-inc-announces-entrance-china\" target=\"_blank\">launch</a> of a digital platform in China through its Vitamin Shoppe Global subsidiary.</li> <li>\"The Asian vitamin, mineral and supplement market is an attractive market for us exhibiting a growth rate of 6% per year and is projected to reach $20 billion in the next five years, according to Nutrition Business Journal, and we are pleased that we are able to secure ease of entry into China,\" says a Vitamin Shoppe exec.</li> <li>Shares of Vitamin Shoppe are <font color='green'>up 11.21%</font> premarket to $5.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298671\" data-linked=\"Vitamin Shoppe higher after launching digital platform in China\" data-tweet=\"$VSI - Vitamin Shoppe higher after launching digital platform in China https://seekingalpha.com/news/3298671-vitamin-shoppe-higher-after-launching-digital-platform-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3298671-vitamin-shoppe-higher-after-launching-digital-platform-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298670\" data-ts=\"1506949675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298670-no-ad-com-review-for-rigels-marketing-application-for-thrombocytopenia-med-fostamatinib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No Ad Com review for Rigel&#39;s marketing application for thrombocytopenia med fostamatinib; shares ahead 14% premarket</a></h4><ul><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) is up&nbsp;<font color='green'>14%</font>&nbsp;premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16955985-rigel-provides-update-fda-review-fostamatinib-itp\" target=\"_blank\">news </a>that the FDA will not hold an advisory committee review for its New Drug Application &#40;NDA&#41; for fostamatinib for the treatment of patients with chronic or persistent immune thrombocytopenia (low blood platelets). The agency's action date is April 17, 2018.</li><li>The company will market the product under the brand name Tavalisse.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298670\" data-linked=\"No Ad Com review for Rigel&#39;s marketing application for thrombocytopenia med fostamatinib; shares ahead 14% premarket\" data-tweet=\"$RIGL - No Ad Com review for Rigel&#39;s marketing application for thrombocytopenia med fostamatinib; shares ahead 14% premarket https://seekingalpha.com/news/3298670-no-ad-com-review-for-rigels-marketing-application-for-thrombocytopenia-med-fostamatinib?source=tweet\" data-url=\"https://seekingalpha.com/news/3298670-no-ad-com-review-for-rigels-marketing-application-for-thrombocytopenia-med-fostamatinib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298666\" data-ts=\"1506949317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNIT\" target=\"_blank\">UNIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298666-uniti-groupminus-1_8-jpmorgan-throws-in-towel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti Group -1.8% as JPMorgan throws in the towel</a></h4><ul><li>Q3 earnings (set for release on Nov. 2) shouldn't be an issue, but Uniti (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) shares could continue to fall until it's confirmed whether or not Windstream's (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) creditor dispute will impact its ability to pay the UNIT lease, says JPMorgan's Philip Cusick.</li><li>Following Unit's 40% plunge over the past two months, he downgrades to Neutral from Overweight, and cuts the price target to a Street-low $16.</li><li>Source: Bloomberg</li><li>Shares&nbsp;<font color='red'>down 1.8%</font>&nbsp;premarket to $14.40. WIN is&nbsp;<font color='green'>up 3.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298666\" data-linked=\"Uniti Group -1.8% as JPMorgan throws in the towel\" data-tweet=\"$UNIT $UNIT $WINMQ - Uniti Group -1.8% as JPMorgan throws in the towel https://seekingalpha.com/news/3298666-uniti-groupminus-1_8-jpmorgan-throws-in-towel?source=tweet\" data-url=\"https://seekingalpha.com/news/3298666-uniti-groupminus-1_8-jpmorgan-throws-in-towel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>123&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298665\" data-ts=\"1506949303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTO\" target=\"_blank\">VSTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298665-vista-outdoor-higher-gun-stocks-in-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vista Outdoor higher with gun stocks in focus</a></h4><ul> <li>Shares of Vista Outdoor (NYSE:<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a>) are <font color='green'>up 1.87%</font> premarket to $23.37 after the mass shooting incident in Las Vegas throws a spotlight on gun stocks.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3298607-gun-stocks-react-mass-shooting-las-vegas\" target=\"_blank\">Gun stocks react to mass shooting in Las Vegas</a> (Oct. 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298659-mgm-resorts-responds-las-vegas-mass-shooting-tragedy\" target=\"_blank\">MGM Resorts responds to Las Vegas mass shooting tragedy</a> (Oct. 2)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298665\" data-linked=\"Vista Outdoor higher with gun stocks in focus\" data-tweet=\"$VSTO - Vista Outdoor higher with gun stocks in focus https://seekingalpha.com/news/3298665-vista-outdoor-higher-gun-stocks-in-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/3298665-vista-outdoor-higher-gun-stocks-in-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298664\" data-ts=\"1506949293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298664-morgan-stanley-downgrades-splunk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley downgrades Splunk</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Morgan+Stanley+Downgrades+Splunk+%28SPLK%29+to+Equalweight/13347368.html\" target=\"_blank\">downgrades</a> Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) from Overweight to Equal Weight with a $77 price target.</li><li>               Analyst Melissa Franchi calls the stock well positioned but thinks sentiment has balanced since last year with few upcoming catalysts.&nbsp;</li><li>               Splunk shares are&nbsp;<font color='red'>down 1.4%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298664\" data-linked=\"Morgan Stanley downgrades Splunk\" data-tweet=\"$SPLK - Morgan Stanley downgrades Splunk https://seekingalpha.com/news/3298664-morgan-stanley-downgrades-splunk?source=tweet\" data-url=\"https://seekingalpha.com/news/3298664-morgan-stanley-downgrades-splunk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298661\" data-ts=\"1506949210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298661-seattle-genetics-adcetris-breakthrough-therapy-for-first-line-hodgkin-lymphoma-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seattle Genetics&#39; Adcetris a Breakthrough Therapy for first-line Hodgkin lymphoma; shares ahead 6% premarket</a></h4><ul><li>Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>) is up<font color='green'> 6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16955871-seattle-genetics-receives-fda-breakthrough-therapy-designation-adcetris-brentuximab-vedotin\" target=\"_blank\">announcement</a> that the FDA has designated ADCETRIS (brentuximab vedotin) a Breakthrough Therapy for the first-line treatment, in combination with chemo, of patients with advanced classical Hodgkin lymphoma.</li><li>Breakthrough Therapy status provides for more intensive FDA guidance on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275463-seattle-genetics-adcetris-chemo-combo-successful-late-stage-lymphoma-study-safety-issues\" target=\"_blank\">Seattle Genetics' Adcetris/chemo combo successful in late-stage lymphoma study, but safety issues concern investors; shares slip 7% premarket</a> (June 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298661\" data-linked=\"Seattle Genetics&#39; Adcetris a Breakthrough Therapy for first-line Hodgkin lymphoma; shares ahead 6% premarket\" data-tweet=\"$SGEN - Seattle Genetics&#39; Adcetris a Breakthrough Therapy for first-line Hodgkin lymphoma; shares ahead 6% premarket https://seekingalpha.com/news/3298661-seattle-genetics-adcetris-breakthrough-therapy-for-first-line-hodgkin-lymphoma-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3298661-seattle-genetics-adcetris-breakthrough-therapy-for-first-line-hodgkin-lymphoma-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298659\" data-ts=\"1506949150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGM\" target=\"_blank\">MGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298659-mgm-resorts-responds-to-las-vegas-mass-shooting-tragedy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MGM Resorts responds to Las Vegas mass shooting tragedy</a></h4><ul> <li>MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) has issued a <a href=\"https://twitter.com/MandalayBay/status/914785831797137408\" target=\"_blank\">statement</a> after the tragic shooting on the Las Vegas Strip last night.</li> <li>The company offered condolences to the victims and says it is cooperating with the investigation. The casino operator said it will provide more detail as they become available.</li> <li>The Las Vegas Police Department confirmed the suspect was killed on the 32nd floor of the Mandalay Bay resort across the street from the concert area where the victims were shot.</li> <li>MGM has a heavy presence on the southern end of the Las Vegas Strip.</li> <li>Shares of MGM are <font color='red'>down 4.33%</font> in premarket action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298659\" data-linked=\"MGM Resorts responds to Las Vegas mass shooting tragedy\" data-tweet=\"$MGM - MGM Resorts responds to Las Vegas mass shooting tragedy https://seekingalpha.com/news/3298659-mgm-resorts-responds-to-las-vegas-mass-shooting-tragedy?source=tweet\" data-url=\"https://seekingalpha.com/news/3298659-mgm-resorts-responds-to-las-vegas-mass-shooting-tragedy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298657\" data-ts=\"1506948868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298657-baird-downgrades-western-digital-on-toshiba-litgation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird downgrades Western Digital on Toshiba litgation</a></h4><ul><li>        Baird <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Downgrades+Western+Digital+Corp.+%28WDC%29+to+Neutral/13346664.html\" target=\"_blank\">downgrades</a> Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Outperform to Neutral and lowers the price target from $120 to $93.</li><li>               Analyst Tristan Gerra cites the ongoing litigation against Toshiba and market conditions that might have less favor for NAND flash pricing next year.&nbsp;</li><li>                  EPS estimates; $11.33 for FY18 and $10.30 for FY19.    </li><li>               Western Digital shares are&nbsp;<font color='red'>down 1.74%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297517-western-digital-comments-arbitrations-filed-toshiba\" target=\"_blank\">Western Digital comments on arbitrations filed against Toshiba</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298657\" data-linked=\"Baird downgrades Western Digital on Toshiba litgation\" data-tweet=\"$WDC - Baird downgrades Western Digital on Toshiba litgation https://seekingalpha.com/news/3298657-baird-downgrades-western-digital-on-toshiba-litgation?source=tweet\" data-url=\"https://seekingalpha.com/news/3298657-baird-downgrades-western-digital-on-toshiba-litgation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298656\" data-ts=\"1506948699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298656-morgan-stanley-ups-outlook-on-sarepta-to-overweight-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley ups outlook on Sarepta to Overweight; shares ahead 4% premarket</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) perks up&nbsp;<font color='green'>4%</font>&nbsp;premarket on average volume on the heels of an upgrade to Overweight by Morgan Stanley based on an improved outlook for DMD med EXONDYS 51.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298656\" data-linked=\"Morgan Stanley ups outlook on Sarepta to Overweight; shares ahead 4% premarket\" data-tweet=\"$SRPT - Morgan Stanley ups outlook on Sarepta to Overweight; shares ahead 4% premarket https://seekingalpha.com/news/3298656-morgan-stanley-ups-outlook-on-sarepta-to-overweight-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298656-morgan-stanley-ups-outlook-on-sarepta-to-overweight-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298653\" data-ts=\"1506948337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAM\" target=\"_blank\">AKAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298653-guggenheim-upgrades-akamai-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim upgrades Akamai Technologies</a></h4><ul><li>           Guggenheim <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Guggenheim+Upgrades+Akamai+Technologies+%28AKAM%29+to+Buy/13347266.html\" target=\"_blank\">upgrades</a> Akamai Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAM' title='Akamai Technologies, Inc.'>AKAM</a>) from Neutral to Buy and ups the price target by one dollar to $54. </li><li> Analyst Mike Hart says the current price offers a bit of safety as the Street underestimates the Media Delivery Solutions potential. </li><li> Akamai shares are&nbsp;<font color='green'>up 0.76%</font>&nbsp;premarket.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3298653\" data-linked=\"Guggenheim upgrades Akamai Technologies\" data-tweet=\"$AKAM - Guggenheim upgrades Akamai Technologies https://seekingalpha.com/news/3298653-guggenheim-upgrades-akamai-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3298653-guggenheim-upgrades-akamai-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}